AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The decision comes as another blow to the European Union's faltering Covid-19 immunization program.

Denmark Is First Country to Permanently Stop Use of AstraZeneca Vaccine

The country was also one of the first to initially suspend AstraZeneca in March.

Denmark Becomes First EU Country To Permanently Block AstraZeneca

Denmark has become the first country to permanently halt the use of AstraZeneca's COVID-19 vaccine following its possible link to very rare cases of blood clots.

Denmark becomes first country to permanently stop use of AstraZeneca vaccine

AstraZeneca Plc (NASDAQ: AZN) said that China's health regulator had expanded the use of Tagrisso in patients with a type of lung cancer when diagnosed at an early stage. China's National Medical Products Administration (NMPA) approved Tagrisso as adjuvant therapy for early-stage lung cancer patients who have a mutation of the EGFR gene.

AstraZeneca's Tagrisso Scores Approval In China For Early Lung Cancer

BioNTech SE

Johnson & Johnson

Moderna

Pfizer

A comparison between COVID-19 vaccines of Pfizer (PFE)/BioNTech (BNTX), Moderna's (MRNA), AstraZeneca (AZN) and J&J (JNJ) is inevitable.

Which Vaccine Maker Will Win the Fight Against COVID-19?

Denmark is set to announce it will halt use of the AstraZeneca vaccine entirely, local media including Politiken reported. The country had agreed to buy 2.4 million doses of the vaccine, which has been linked to blood-clotting concerns.

Denmark to halt use of AstraZeneca vaccine altogether: reports

AstraZeneca PLC (LON:AZN) and Johnson & Johnson (NYSE:JNJ) are not expected to get their COVID-19 vaccine contracts renewed by the EU Commission. The bloc is planning to focus on mRNA-based vaccines, such as those produced by Pfizer and Moderna, Italian newspaper La Stampa reported.

AstraZeneca, Johnson & Johnson not expected to have COVID-19 vaccine contracts renewed by EU

AstraZeneca PLC (LON:AZN) announced that Tagrisso (osimertinib) has been approved in China for the adjuvant treatment of patients with early-stage lung cancer. It is aimed at patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) who have had surgery to remove the tumour, and can be used with or without chemotherapy as recommended by the patient's physician.

AstraZeneca receives approval in China for early-stage lung cancer treatment Tagrisso

Federal health officials say the ultra-rare blood clots reported in six people who received Johnson & Johnson's COVID-19 vaccine are similar to blood clots detected in a very small number of people in Europe who were immunized with AstraZeneca's shot.

Rare blood clots tied to J&J's COVID-19 shot are similar to issues with AstraZeneca's vaccine, FDA official says

AstraZeneca's (AZN) phase III study on Farxiga in hospitalized COVID-19 patients with pre-existing health conditions fails to show statistical significance for the primary endpoint

AstraZeneca (AZN) Farxiga COVID-19 Study Fails to Meet Goal

The U.S. health chief isn't visiting restaurants and says this is no time to prematurely declare victory on COVID-19.

AstraZeneca shot may never get used in the U.S., says Fauci — it may not be needed

The country's top infectious disease official said the AstraZeneca shot was good from an efficacy standpoint but safety issues around rare blood clots need to get straightened out.

U.S. Will Likely Not Need AstraZeneca Vaccine But Shot Has Good Efficacy, Says Dr. Fauci

The odds of experiencing a fatal blood clot following inoculation with AstraZeneca's COVID-19 vaccine are less than one in a million, but that was enough to spook Argus Research.

Analyst Downgrades AstraZeneca Stock Due to Vaccine Side Effect Concerns

Novavax

Regeneron Pharmaceuticals

Nearly everyone will get the Covid-19 vaccination, suggesting strong revenue for a handful of pharmaceutical companies. The post Vaccine Passport Potential Could Boost These 7 Pharmaceutical Stocks appeared first on InvestorPlace.

Vaccine Passport Potential Could Boost These 7 Pharmaceutical Stocks

Bumble

McDonald's

Microsoft

Crown Castle International

Codexis

International Flavors & Fragrances

Motorola Solutions

Radius Global Infrastructure Inc

With the trading day about halfway over, the broad markets were pulling back. All the major averages were reeling, especially the Nasdaq, on concerns over the global semiconductor shortage.

AstraZeneca, Bumble, McDonald's, Microsoft and More Monday Afternoon Analyst Calls

Up to 80% of people in Sicily are turning down the AstraZeneca vaccine when it is offered, the island's leader said on Saturday.  Nello Musumeci, Sicily's president said in a press conference on Saturday that "out of 100 people, 80 say no" to the AstraZeneca vaccine, AFP reported.

The leader of Sicily in Italy said as many as 80% of people are turning down the AstraZeneca jab

AstraZeneca Plc (NASDAQ: AZN) said Monday its diabetes drug Farxiga failed to achieve the main endpoints in a late-stage trial, dubbed DARE-19, for effectiveness against COVID-19. What Happened: The U.K.-based drugmaker's trial showed that Farxiga doesn't reduce the risk of the disease worsening or death.

AstraZeneca Farxiga Drug Doesn't Work Against COVID-19

AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine has recently dominated headlines after cases of rare blood clots were reported in European countries. Now, European Medical Agency (EMA) is investigating potential clotting risks from Johnson & Johnson's (NYSE: JNJ) one-shot COVID-19 vaccine.

Johnson & Johnson's COVID-19 Vaccine Under Review At EMA For Blood Clots, AstraZeneca Probe Expanded

AstraZeneca's COVID-19 vaccine can lead to blood clots in rare cases, according to new research published Friday in The New England Journal of Medicine.

New research ties AstraZeneca's COVID-19 shots with rare blood clots

Controversy over AstraZeneca's Covid-19 vaccine has sparked some investor concerns about its stock, according to Jefferies – but it's not all bad news for the British pharmaceutical company.

AstraZeneca: Analysts point to promising pipeline despite Covid vaccine jitters

AbbVie

ACADIA Pharma

Alexion Pharma

Biogen

CRISPR Therapeutics

Editas Medicine

Illumina

Kadmon Hlds

Regulatory and drug-pricing worries have knocked biotech stocks off their Covid-19 pedestal. After hitting a high point in early February, biotech stocks have collectedly fallen 21%.

Biotech Stocks Hit A Snag — Why Experts Say The Heyday Isn't Over

AstraZeneca's vaccine is key to ending the global economic slump caused by the coronavirus. But a series of missteps by the drugmaker and new concerns over blood clots risk undermining public confidence in the shot and delaying the recovery.

How AstraZeneca's latest vaccine troubles could slow the global recovery

At least seven countries have restricted the shots use in younger people despite regulators asserting the safety and efficacy of the vaccines.

Here's Why These Countries Are Reconsidering The AstraZeneca Covid-19 Vaccine — Even Though Experts Say It's Safe

European regulators find a possible link between AstraZeneca's (AZN) COVID-19 vaccine and rare blood clot events.

AstraZeneca (AZN) COVID-19 Jab May Have Link to Rare Blood Clots

The UK has enough COVID-19 vaccines to offer to young people as an alternative to the AstraZeneca PLC (LON:AZN) jab, health secretary Matt Hancock said. He told the BBC there is "more than enough of the Pfizer or Moderna vaccine" for the 8.5mln residents aged between 18 and 29.

UK has enough COVID-19 vaccines for under 30s after decision on AstraZeneca jab, says minister

News for AstraZeneca Stock (AZN)